Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2011

01-10-2011 | Case Report

Renal amyloidosis caused by apolipoprotein A-II without a genetic mutation in the coding sequence

Authors: Ryuji Morizane, Toshiaki Monkawa, Konosuke Konishi, Akinori Hashiguchi, Mitsuharu Ueda, Yukio Ando, Hirobumi Tokuyama, Koichi Hayashi, Matsuhiko Hayashi, Hiroshi Itoh

Published in: Clinical and Experimental Nephrology | Issue 5/2011

Login to get access

Abstract

Although the majority of renal amyloidosis is caused by either acquired monoclonal immunoglobulin light-chain amyloidosis or reactive systemic amyloid A, some cases are caused by hereditary amyloidosis. Apolipoprotein A-II (apoAII) amyloidosis is a rare form of hereditary amyloidosis and cannot be diagnosed by a routine examination. Thus, the prevalence and etiology of apoAII amyloidosis are uncertain. In humans, a genetic mutation in the stop codon of apoAII is considered to be a cause of amyloid fibril formation. We report on a 68-year-old man who presented with proteinuria by apoAII amyloidosis without family history. His proteinuria gradually increased to 6 g/day within 1 year. A renal biopsy showed amyloid deposition in the glomeruli, however, acquired monoclonal immunoglobulin light-chain amyloidosis and reactive systemic amyloid A were ruled out. Immunohistochemistry revealed apoAII deposition in the glomeruli, but DNA sequencing did not identify any genetic mutation in the coding sequence of apoAII. Here, we report a case of apoAII amyloidosis without a genetic mutation in the coding sequence and discuss the etiology of apoAII amyloidosis.
Literature
1.
go back to reference Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786–91.CrossRefPubMed Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346:1786–91.CrossRefPubMed
3.
go back to reference Murphy CL, Wang S, Kestler D, Larsen C, Benson D, Weiss DT, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis. 2010;56:1100–7.CrossRefPubMedPubMedCentral Murphy CL, Wang S, Kestler D, Larsen C, Benson D, Weiss DT, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis. 2010;56:1100–7.CrossRefPubMedPubMedCentral
4.
go back to reference Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, et al. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem. 2009;55:1223–7.CrossRefPubMed Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, et al. SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem. 2009;55:1223–7.CrossRefPubMed
5.
go back to reference von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Röcken C. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. 2009;33:1198–205.CrossRef von Hutten H, Mihatsch M, Lobeck H, Rudolph B, Eriksson M, Röcken C. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. 2009;33:1198–205.CrossRef
6.
go back to reference Higuchi K, Yonezu T, Kogishi K, Matsumura A, Takeshita S, Higuchi K, et al. Purification and characterization of a senile amyloid-related antigenic substance (apoSASSAM) from mouse serum apoSASSAM is an apoA-II apolipoprotein of mouse high density lipoproteins. J Biol Chem. 1986;261:12834–40.PubMed Higuchi K, Yonezu T, Kogishi K, Matsumura A, Takeshita S, Higuchi K, et al. Purification and characterization of a senile amyloid-related antigenic substance (apoSASSAM) from mouse serum apoSASSAM is an apoA-II apolipoprotein of mouse high density lipoproteins. J Biol Chem. 1986;261:12834–40.PubMed
7.
go back to reference Higuchi K, Kitagawa K, Naiki H, Hanada K, Hosokawa M, Takeda T. Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J. 1991;279:427–33.CrossRefPubMedPubMedCentral Higuchi K, Kitagawa K, Naiki H, Hanada K, Hosokawa M, Takeda T. Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. Biochem J. 1991;279:427–33.CrossRefPubMedPubMedCentral
8.
go back to reference Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, Guenther B, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics. 2001;72:272–7.CrossRefPubMed Benson MD, Liepnieks JJ, Yazaki M, Yamashita T, Hamidi Asl K, Guenther B, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics. 2001;72:272–7.CrossRefPubMed
9.
go back to reference Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int. 2003;64:11–6.CrossRefPubMed Yazaki M, Liepnieks JJ, Barats MS, Cohen AH, Benson MD. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int. 2003;64:11–6.CrossRefPubMed
10.
go back to reference Yazaki M, Liepnieks JJ, Yamashita T, Guenther B, Skinner M, Benson MD. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int. 2001;60:1658–65.CrossRefPubMed Yazaki M, Liepnieks JJ, Yamashita T, Guenther B, Skinner M, Benson MD. Renal amyloidosis caused by a novel stop-codon mutation in the apolipoprotein A-II gene. Kidney Int. 2001;60:1658–65.CrossRefPubMed
11.
go back to reference Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003;10(Suppl 1):48–54.PubMed Westermark P, Bergström J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003;10(Suppl 1):48–54.PubMed
12.
go back to reference Xing Y, Nakamura A, Chiba T, Kogishi K, Matsushita T, Li F, et al. Transmission of mouse senile amyloidosis. Lab Invest. 2001;81:493–9.CrossRefPubMed Xing Y, Nakamura A, Chiba T, Kogishi K, Matsushita T, Li F, et al. Transmission of mouse senile amyloidosis. Lab Invest. 2001;81:493–9.CrossRefPubMed
13.
go back to reference Korenaga T, Yan J, Sawashita J, Matsushita T, Naiki H, Hosokawa M, et al. Transmission of amyloidosis in offspring of mice with AApoAII amyloidosis. Am J Pathol. 2006;168:898–906.CrossRefPubMedPubMedCentral Korenaga T, Yan J, Sawashita J, Matsushita T, Naiki H, Hosokawa M, et al. Transmission of amyloidosis in offspring of mice with AApoAII amyloidosis. Am J Pathol. 2006;168:898–906.CrossRefPubMedPubMedCentral
14.
go back to reference Qian J, Yan J, Ge F, Zhang B, Fu X, Tomozawa H et al. Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity. PLoS Pathog. 2010;6:e1000914.CrossRefPubMedPubMedCentral Qian J, Yan J, Ge F, Zhang B, Fu X, Tomozawa H et al. Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity. PLoS Pathog. 2010;6:e1000914.CrossRefPubMedPubMedCentral
Metadata
Title
Renal amyloidosis caused by apolipoprotein A-II without a genetic mutation in the coding sequence
Authors
Ryuji Morizane
Toshiaki Monkawa
Konosuke Konishi
Akinori Hashiguchi
Mitsuharu Ueda
Yukio Ando
Hirobumi Tokuyama
Koichi Hayashi
Matsuhiko Hayashi
Hiroshi Itoh
Publication date
01-10-2011
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2011
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-011-0483-4

Other articles of this Issue 5/2011

Clinical and Experimental Nephrology 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.